|
US6127341A
(en)
*
|
1997-06-20 |
2000-10-03 |
Novo Nordisk A/S |
Compounds with growth hormone releasing properties
|
|
JP4116097B2
(ja)
*
|
1997-06-20 |
2008-07-09 |
ノボ ノルディスク アクティーゼルスカブ |
成長ホルモン放出特性をもつ化合物
|
|
DE69941255D1
(de)
*
|
1998-05-11 |
2009-09-24 |
Novo Nordisk As |
Verbindungen mit wachstumshormon freisetzenden eigenschaften
|
|
TW450954B
(en)
*
|
1998-05-14 |
2001-08-21 |
Pharmacia & Amp Upjohn Company |
Phenylsulfonamide-phenylethylamines useful as dopamine receptors
|
|
DE69943239D1
(de)
*
|
1998-06-30 |
2011-04-14 |
Novo Nordisk As |
Verbindungen mit wachstumshormon-freisetzenden eigenschaften
|
|
US6919315B1
(en)
|
1998-06-30 |
2005-07-19 |
Novo Nordisk A/S |
Compounds with growth hormone releasing properties
|
|
US6358951B1
(en)
*
|
1998-08-21 |
2002-03-19 |
Pfizer Inc. |
Growth hormone secretagogues
|
|
EP1930021A3
(en)
|
1999-02-18 |
2008-06-18 |
Kaken Pharmaceutical Co., Ltd. |
Novel amide derivatives as growth hormone secretagogues
|
|
UA73530C2
(uk)
*
|
1999-11-10 |
2005-08-15 |
Ново Нордіск А/С |
Сполука з властивостями вивільнювати гормон росту
|
|
DE60124080T2
(de)
|
2000-03-23 |
2007-03-01 |
Elan Pharmaceuticals, Inc., San Francisco |
Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
|
|
US6992081B2
(en)
|
2000-03-23 |
2006-01-31 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
|
US6613801B2
(en)
*
|
2000-05-30 |
2003-09-02 |
Transtech Pharma, Inc. |
Method for the synthesis of compounds of formula I and their uses thereof
|
|
US7087632B2
(en)
*
|
2001-03-05 |
2006-08-08 |
Transtech Pharma, Inc. |
Benzimidazole derivatives as therapeutic agents
|
|
ES2333097T3
(es)
|
2000-05-31 |
2010-02-17 |
Raqualia Pharma Inc |
Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
|
|
EP1666452A2
(en)
|
2000-06-30 |
2006-06-07 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
|
US20030096864A1
(en)
*
|
2000-06-30 |
2003-05-22 |
Fang Lawrence Y. |
Compounds to treat alzheimer's disease
|
|
US6846813B2
(en)
*
|
2000-06-30 |
2005-01-25 |
Pharmacia & Upjohn Company |
Compounds to treat alzheimer's disease
|
|
US7034182B2
(en)
*
|
2000-06-30 |
2006-04-25 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
|
PE20020276A1
(es)
|
2000-06-30 |
2002-04-06 |
Elan Pharm Inc |
COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
|
|
KR100900020B1
(ko)
*
|
2001-02-16 |
2009-06-01 |
알레릭스 뉴로사이언스, 인크. |
Ｇｌｙｔ-1 저해제로서의 티오펜 치환 아민 유도체
|
|
EP1377295A4
(en)
*
|
2001-03-05 |
2007-05-09 |
Transtech Pharma Inc |
CARBOXYL ACID DERIVATIVES THERAPEUTIC AGENTS
|
|
BR0210721A
(pt)
*
|
2001-06-27 |
2004-07-20 |
Elan Pharm Inc |
Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição
|
|
US20070213407A1
(en)
*
|
2001-06-29 |
2007-09-13 |
Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc |
Compounds to treat Alzheimer's disease
|
|
WO2003059880A1
(en)
*
|
2002-01-11 |
2003-07-24 |
Sankyo Company, Limited |
Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
|
|
US7230133B2
(en)
|
2003-05-01 |
2007-06-12 |
Bristol-Myers Squibb Company |
Malonamides and malonamide derivatives as modulators of chemokine receptor activity
|
|
WO2005000295A1
(en)
*
|
2003-05-20 |
2005-01-06 |
Transtech Pharma, Inc. |
Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
|
|
US7476653B2
(en)
|
2003-06-18 |
2009-01-13 |
Tranzyme Pharma, Inc. |
Macrocyclic modulators of the ghrelin receptor
|
|
WO2005027913A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Pfizer Products Inc. |
Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
|
|
EP1733724A4
(en)
|
2004-02-24 |
2010-07-07 |
Sankyo Co |
Aminoalcohol compound
|
|
EP1735055A1
(en)
*
|
2004-03-30 |
2006-12-27 |
Sapphire Therapeutics, Inc. |
Method of reducing c-reactive protein using growth hormone secretagogues
|
|
CN103772483A
(zh)
*
|
2004-06-29 |
2014-05-07 |
赫尔辛医疗股份公司 |
（3r）－1－（2－甲基丙氨酰－d－色氨酰）－3－（苯甲基）－3－哌啶羧酸1,2,2－三甲基酰肼的晶形
|
|
AU2005272598B2
(en)
*
|
2004-08-12 |
2011-11-17 |
Helsinn Therapeutics (U.S.), Inc. |
Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
|
|
CN101248184B
(zh)
|
2005-08-25 |
2013-01-16 |
宇部兴产株式会社 |
光学活性（S或R）-α-氨基酸及光学活性（S或R）-α-氨基酸酯的制造方法
|
|
CU23558A1
(es)
|
2006-02-28 |
2010-07-20 |
Ct Ingenieria Genetica Biotech |
Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
|
|
US8889632B2
(en)
|
2007-01-31 |
2014-11-18 |
Dana-Farber Cancer Institute, Inc. |
Stabilized p53 peptides and uses thereof
|
|
EA200901077A1
(ru)
|
2007-02-09 |
2010-04-30 |
Транзим Фарма, Инк. |
Макроциклические модуляторы грелинового рецептора и их применение
|
|
MX2009008561A
(es)
*
|
2007-02-13 |
2010-01-15 |
Helsinn Therapeutics Us Inc |
Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.
|
|
JP5631201B2
(ja)
|
2007-03-28 |
2014-11-26 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ステッチングされたポリペプチド
|
|
TWI429436B
(zh)
*
|
2007-04-10 |
2014-03-11 |
Helsinn Therapeutics Us Inc |
使用生長激素促泌素治療或預防嘔吐之方法
|
|
UA105657C2
(uk)
|
2009-02-27 |
2014-06-10 |
Хелсінн Терапьютікс (Ю.Ес.), Інк. |
Поліпшені способи лікування мігрені на основі анамореліну
|
|
CA2772797C
(en)
|
2009-09-30 |
2018-09-25 |
Transtech Pharma, Inc. |
Substituted imidazole derivatives
|
|
KR20180058866A
(ko)
|
2010-08-13 |
2018-06-01 |
에일러론 테라퓨틱스 인코포레이티드 |
펩티도미메틱 거대고리
|
|
BR112014009418A2
(pt)
|
2011-10-18 |
2017-04-18 |
Aileron Therapeutics Inc |
macrociclos peptidomiméticos
|
|
CN112500466B
(zh)
|
2012-02-15 |
2022-05-03 |
艾瑞朗医疗公司 |
拟肽大环化合物
|
|
WO2013123267A1
(en)
|
2012-02-15 |
2013-08-22 |
Aileron Therapeutics, Inc. |
Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
|
|
US9717710B2
(en)
|
2012-10-05 |
2017-08-01 |
Vtv Therapeutics Llc |
Treatment of mild and moderate Alzheimer's disease
|
|
MX2015005244A
(es)
|
2012-11-01 |
2015-07-14 |
Aileron Therapeutics Inc |
Aminoacidos disustituidos y metodos de preparacion y el uso de los mismos.
|
|
US9119832B2
(en)
|
2014-02-05 |
2015-09-01 |
The Regents Of The University Of California |
Methods of treating mild brain injury
|
|
AU2015320549A1
(en)
|
2014-09-24 |
2017-04-13 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
|
SG11201707750YA
(en)
|
2015-03-20 |
2017-10-30 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles and uses thereof
|
|
US20170121385A1
(en)
|
2015-10-28 |
2017-05-04 |
Oxeia Biopharmaceuticals, Inc. |
Methods of treating neurodegenerative conditions
|
|
EP3414783B1
(en)
|
2016-02-09 |
2021-08-18 |
Lumeova, Inc |
Ultra-wideband, wireless optical high speed communication devices and systems
|
|
WO2019190822A1
(en)
|
2018-03-28 |
2019-10-03 |
Vtv Therapeutics Llc |
Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
|
|
WO2019190823A1
(en)
|
2018-03-28 |
2019-10-03 |
Vtv Therapeutics Llc |
Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
|
|
WO2020076668A1
(en)
|
2018-10-10 |
2020-04-16 |
Vtv Therapeutics Llc |
Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine
|